All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

Product Type

Companies

Mycenax Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

TAIWAN Taiwan

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Hummingbird Bioscience Announces Agreement with Mycenax Biotech for Production of Anti-VISTA Antibody

Lead Product(s): HMBD-002

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Hummingbird Bioscience

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 20, 2020

Details:

Pre-clinical studies have shown that HMBD-002 can strongly inhibit tumor growth, both as a monotherapy and even more potently when combined with anti-PD(L)1 treatment.